来自巨藻和微藻的天然生物活性化合物用于治疗阿尔茨海默病:一篇评论
Jia Yee Lee1, Chiew Yen Wong2, Rhun Yian Koh2
1School of Health Sciences, International Medical University, Kuala Lumpur, Malaysia.
The Yale journal of biology and medicine
|July 1, 2024
概括
海洋藻类化合物在治疗阿尔茨海默病 (AD) 方面表现有前途. 这些天然物质通过对抗炎症和氧化应激来提供神经保护,这是AD进展的关键因素.
科学领域:
- 海洋生物技术 海洋生物技术
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经退行性疾病,如阿尔茨海默氏症 (AD),以神经炎症,有毒蛋白质聚合,氧化应激和线粒体功能障碍为特征.
- 有效的AD治疗需要使用抗氧化剂,抗炎剂和粉样β (Aβ) 形成抑制剂准这些核心病理机制.
- 海洋藻类是多种生物活性化合物的宝贵来源,具有显著的制药和营养潜力.
研究的目的:
- 探索来自海洋藻类的生物活性化合物的神经保护潜力,用于阿尔茨海默病 (AD) 管理.
- 阐明AD模型中藻类化合物的神经保护作用背后的分子机制.
- 讨论这些化合物的应用作为疾病修饰和阿尔茨海默病的症状治疗策略.
主要方法:
- 关于海洋藻类生物活性化合物及其生物活动的现有文献的审查.
- 对神经炎症和阿尔茨海默病 (AD) 的体外和体内模型进行分析.
- 研究藻类化合物所准的分子通路,包括抗氧化和抗炎机制.
主要成果:
- 海藻产生丰富的生物活性化合物,包括,胡卜素和维生素,具有已证明的抗炎和抗氧化特性.
- 有证据表明,这些藻类化合物具有与阿尔茨海默氏症 (AD) 病理学相关的显著神经保护作用.
- 藻类化合物向关键AD途径,如神经炎症,氧化应激和蛋白质聚合.
结论:
- 来自海洋藻类的生物活性化合物对预防和治疗阿尔茨海默病 (AD) 具有相当大的潜力.
- 这些化合物为开发针对AD复杂机制的新型治疗策略提供了有希望的途径.
- 对藻类化合物的进一步研究可能会导致对AD的有效疾病修饰和症状治疗.
更多相关视频
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.5K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
相关概念视频
Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
